Clinically significant thromboembolic disease in orthopedic oncology: An analysis of 986 patients treated with low molecular-weight heparin.

摘要

In this issue, the authors Ruggeiri et al. report on "Clinically significant thromboembolic disease in orthopedic oncology: an analysis of 986 patients treated with low molecular-weight heparin." The authors present a large series of patients undergoing major resections and reconstructions and quote a 1.1 % incidence of clinically significant thromboembolic disease. The issue of appropriate and safe treatment for the prophylaxis of thromboembolic disease is currently a much debated topic in orthopedic surgery, and the inclusion of a malignant diagnosis adds a degree of complexity to the discussion. Despite the recent heightened awareness and various treatment strategies available, the incidence of thromboembolic disease in the general population has essentially remained unchanged since the 1980s [1].